Cardiovascular Diabetology

Table 3 Correlation analysis of LDL size with lipid profile, modified LDLs, HDL composition and Lp-PLA2 activity in patients with type 2 diabetes and control subjects

From: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

	DM2 patients		Control subjects
	R	P	R	P
HbA1c	−0.160	0.071	−0.103	0.601
Insulin	−0.076	0.418	0.008	0.937
Total cholesterol	−0.185	0.035	−0.326	0.016
Triglycerides	−0.553	< 0.001	−0.427	0.001
VLDLc	−0.513	< 0.001	−0.423	0.001
LDLc	−0.152	0.083	−0.333	0.014
HDLc	0.407	< 0.001	0.096	0.491
NEFA	−0.226	0.004	−0.042	0.765
apoB	−0.246	0.005	−0.458	< 0.001
apoA-I	0.264	0.002	−0.033	0.811
apoA-II	−0.068	0.472	−0.099	0.476
Oxidized LDL	−0.390	< 0.001	−0.472	< 0.001
Glycated LDL	−0.273	0.003	−0.151	0.307
LDL(-)	−0.020	0.828	0.030	0.849
Cholesterol in HDL	0.321	0.002	0.208	0.244
Trigycerides in HDL	−0.398	< 0.001	−0.150	0.405
Phospholipids in HDL	0.437	< 0.001	0.067	0.712
apoA-I in HDL	−0.205	0.047	0.086	0.635
apoA-II in HDL	−0.169	0.103	−0.069	0.739
NEFA in HDL	−0.010	0.925	0.086	0.635
PON1	0.016	0.867	0.024	0.872
Total Lp-PLA2 activity	−0.123	0.172	0.025	0.862
HDL-Lp-PLA2 activity	0.030	0.745	0.061	0.680
% of HDL-Lp-PLA2	0.191	0.034	0.064	0.662

Bold type indicates the loss of statistical significance in the control group compared to diabetic patients.

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com